Also see: Charles Schwab, Polaris: Analysts' New Ratings

Editor's Note: Green and red arrows refer to intraday stock price movement.

NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES

Apple ( AAPL - Get Report) price target boosted at Citi to $435 from $415. Another iPhone-driven blow out quarter, Citigroup said. Maintain Buy rating.

Apple ( AAPL - Get Report) estimates, target upped at UBS. AAPL estimates were boosted through 2012, UBS said. iPhone sales continue to drive growth. Buy rating and new $495 price target.

Abbott Laboratories ( ABT - Get Report) estimates upped at Morgan Stanley through 2012. Company is seeing better Humira sales. Overweight rating and $55 price target.

Albemarle ( ALB - Get Report) price target raised at Citi to $75 from $70. Impressive 1Q11 beat, firing on all cylinders, Citigroup said. Maintain Buy rating.

Altria ( MO - Get Report) estimates increased at UBS through 2012, UBS said. Company is seeing better pricing power. Buy rating and $28 price target.

American Express ( AXP) estimates boosted at Morgan Stanley through 2012, Morgan Stanley said. Company is releasing reserves and cutting costs. Overweight rating and $53 price target.

Cree ( CREE) estimates, target cut at UBS. Shares of CREE now seen reaching $41, according to UBS. Estimates also reduced, as the company has limited visibility. Neutral rating.

Quest Diagnostics ( DGX) price target higher at Citi. DGX shares now seen reaching $61, up from $58. Valuation too cheap for solid 1Q11 results, Citigroup said. Maintain Hold rating.

EMC ( EMC) price target raised at Citi to $32 from $28. Strong storage revenue, best is yet to come, Citigroup said. Maintain Buy rating.

EMC ( EMC) estimates, target raised at UBS. Shares of EMC now seen reaching $32, according to UBS. Estimates also increased, as new products are driving growth. Buy rating.

Eaton ( ETN) estimates, target boosted at UBS. Shares of ETN now seen reaching $57, according to UBS. Estimates also upped, given better end-market demand. Neutral rating.

Edwards LifeSciences ( EW) estimates upped at Morgan Stanley through 2012. Company is seeing favorable currency changes. Equal-weight rating.

F5 Networks ( FFIV) price target raised at Credit Suisse to $146 from $134. Strong 2Q11, plenty of room for upside, Credit Suisse said. Maintain Outperform rating.

Hanesbrands ( HBI) price target higher at Citi to $39 from $33. Significant 1Q11 beat, expect continued upside, Citigroup said. Maintain Buy rating.

Knight Transportation ( KNX) price target lower at Citi to $21 from $23 on disappointing 1Q11, Citigroup said. Maintain Buy rating.

Knight Transportation ( KNX) estimates reduced at Morgan Stanley through 2013. Company is seeing lower utilization rates and paying higher fuel costs. Equal-weight rating.

Lam Research ( LRCX) estimates lowered at UBS through 2012. Company is spending more on R&D. Buy rating and $59 price target.

Newfield Exploration ( NFX) numbers lowered at UBS. Shares of NFX now seen reaching $81. Estimates also cut, given the company's higher unit costs. Buy rating.

Qualcomm ( QCOM - Get Report) price target raised at Citi to $67 from $60 as smartphones drive strong sales, Citigroup said. Maintain buy rating.

Qualcomm ( QCOM - Get Report) estimates, target increased at UBS. QCOM estimates were raised through 2012, UBS said. Company remains leveraged to rising smartphone demand. Buy rating and new $70 price target.

Ralcorp ( RAH) estimates, target raised at UBS. Shares of RAH now seen reaching $70, according to UBS. Estimates also increased, as the company is seeing higher private-label sales. Neutral rating.

United Technologies ( UTX) price target boosted at Citi to $91 from $89. Carrier drives 1Q11 beat, further 2011 guidance increases, Citigroup said. Maintain Hold rating.

End of report.

This article was written by a staff member of TheStreet.